Mycosis Fungoides (Cutaneous T-Cell Lymphoma)
Table of Contents
Overview and Epidemiology
Mycosis fungoides (MF) is the most common primary cutaneous lymphoma, accounting for approximately 50% of all cutaneous lymphomas. Despite its alarming name — coined by French dermatologist Jean-Louis-Marc Alibert in 1806 after observing mushroom-shaped skin tumors — the disease follows a surprisingly indolent course in most patients, progressing over years to decades rather than months.
MF belongs to the broader category of cutaneous T-cell lymphomas (CTCL), a group of non-Hodgkin lymphomas arising from skin-homing T lymphocytes. The malignant cells are epidermotropic CD4+ T cells — they have an abnormal drive to enter and accumulate within the outer layers of the skin.
Key epidemiological facts:
- Incidence: approximately 3–4 cases per million persons per year in the United States
- Age: primarily a disease of adults, with a median age at diagnosis of 55–60 years; rarely occurs in children
- Sex: male predominance at roughly 2:1
- Race: higher incidence and worse outcomes reported in Black Americans compared to White Americans
- Course: most patients remain at early (patch/plaque) stage for decades; only a minority progress to tumor or erythrodermic stage
- Diagnostic delay: average of 4–6 years from first skin changes to confirmed diagnosis, because early MF closely mimics benign inflammatory conditions
Pathophysiology and Immunophenotype
The hallmark of MF is the clonal proliferation of mature, post-thymic CD4+ CD45RO+ memory T cells that have acquired an abnormal drive to home to the epidermis (epidermotropism). In normal immunity, these memory T cells patrol skin tissue; in MF, a clone of these cells accumulates, evades immune surveillance, and eventually transforms into frank lymphoma.
Immunophenotypic profile:
- CD3+ (pan-T-cell marker; positive)
- CD4+ (helper T-cell subset; positive in classic MF)
- CD45RO+ (memory T-cell isoform; positive)
- CD5 loss and CD7 loss — as MF progresses, malignant T cells frequently lose expression of CD5 and CD7 (pan-T antigens that are normally present). This loss of surface antigens is an important immunophenotypic clue that distinguishes MF from benign inflammatory infiltrates, where CD5 and CD7 are retained.
- CD8– in classic MF (rare CD8+ MF variants exist)
Clonal T-cell receptor (TCR) gene rearrangement is detectable by polymerase chain reaction (PCR) in involved skin and, in advanced disease, in peripheral blood. Identifying the same clone in both skin and blood is central to diagnosing Sézary syndrome. Clonality alone does not establish malignancy — benign conditions can show oligoclonal or even apparently clonal expansions — but TCR clonality in the appropriate clinical and histological context strongly supports the diagnosis of MF.
The precise molecular initiating event is unknown. Candidate pathways include chronic antigen stimulation, JAK-STAT signaling dysregulation, loss of tumor suppressor function (CDKN2A deletion is common), and epigenetic silencing. Transformation to large-cell lymphoma (CD30+ or CD30–) can occur in advanced disease and carries a worse prognosis.
Clinical Stages (TNMB Staging)
MF is staged using the TNMB system — Tumor extent in skin (T), lymph Node involvement (N), visceral organ involvement (M), and Blood involvement (B). Understanding the clinical appearance at each stage is critical because early MF is notoriously difficult to distinguish from common benign skin conditions.
Patch Stage (Stage IA / IB)
In the International Society for Cutaneous Lymphomas / European Organization for Research and Treatment of Cancer (ISCL/EORTC) staging used in the National Cancer Institute's summary, stage IA means patches, papules or plaques covering less than 10% of the skin, and stage IB means they cover 10% or more, with no abnormal lymph nodes and no organ involvement.
Patches are flat, subtle, scaly erythematous lesions that are frequently misdiagnosed for years as eczema, psoriasis, tinea corporis, or contact dermatitis. Distinguishing features that point toward MF include:
- "Bathing suit" distribution: patches typically favor sun-protected areas — buttocks, breasts, medial thighs, and lower abdomen. This contrasts with psoriasis, which classically favors extensor surfaces (knees, elbows), and with contact dermatitis, which follows exposure patterns.
- Poikiloderma (skin wrinkle sign): a characteristic triad of atrophy (thinning), mottled pigmentation changes, and telangiectasias (dilated capillaries) in the same lesion. This poikilodermatous appearance, especially in sun-protected sites, is a strong clinical clue.
- Pruritus: often severe, disproportionate to the appearance of the skin, and poorly responsive to standard antipruritic treatments.
- Chronicity: lesions persist for months to years without changing in response to standard topical therapies.
Most patients remain at the patch stage for many years to decades. Stage IA disease (patches covering less than 10% of body surface area) has a near-normal life expectancy with appropriate skin-directed treatment.
Plaque Stage (Stage IA / IB) and Stage IIA (Abnormal Lymph Nodes)
Plaques are thicker, raised, indurated lesions that develop superimposed on, or in place of, existing patches. They may be more intensely erythematous, more pruritic, and show more obvious scaling. In the staging table, plaques count the same way as patches: under 10% of the skin is stage IA and 10% or more is stage IB. Stage IIA is the same patch or plaque picture plus clinically abnormal lymph nodes. At stage IIA, lymph nodes may be palpably enlarged (reactive adenopathy or early involvement), but lymph node biopsy shows only dermatopathic changes without frank lymphomatous involvement.
Tumor Stage (Stage IIB) and Erythroderma (Stage III)
The tumor stage is defined by the emergence of raised, nodular tumors — the "mushroom-shaped projections" that gave the disease its name when Alibert first described it in 1806. One or more tumors of 1 cm or more across define stage IIB. Tumors may ulcerate and become secondarily infected. Prognosis worsens significantly at this stage. Stage III describes diffuse redness of the skin (erythroderma) covering 80% or more of the body surface, without high blood involvement.
Sézary Syndrome — Erythrodermic / Leukemic Variant (Stage IVA1)
Sézary syndrome (SS) is the leukemic variant of CTCL and represents the most severe form of the disease. In the staging table, a high blood count of Sézary cells (B2) places the disease at stage IVA1, whatever the skin stage; stage IVA2 means lymph nodes taken over by lymphoma (N3). Diagnostic criteria require the triad of:
- Erythroderma: confluent redness and scaling covering ≥80–90% of the body surface area — the dramatic "red man" appearance.
- Sézary cells in blood: atypical lymphocytes with characteristic cerebriform (convoluted, brain-like) nuclei visible on peripheral blood smear; diagnostic threshold is ≥1,000 Sézary cells/µL, or a CD4/CD8 ratio greater than 10, or CD4+CD7– cells ≥40% of CD4+ lymphocytes.
- Lymphadenopathy: enlarged lymph nodes with histologically confirmed CTCL involvement.
Additional features include severe, debilitating pruritus; fissuring of the palms and soles; ectropion (eyelid eversion); and total alopecia. Sézary syndrome carries a median survival of 2–4 years from diagnosis, making it the most challenging CTCL to manage.
Visceral Stage (Stage IVB)
Stage IVB involves spread to visceral organs — liver, lung, spleen, or bone marrow. This stage carries the worst prognosis and requires systemic chemotherapy approaches, with consideration of allogeneic stem cell transplantation in eligible patients.
Diagnosis
Diagnosis of MF is notoriously challenging and requires integration of clinical, histopathological, immunophenotypic, and molecular data. No single finding is diagnostic; the diagnosis is established by the overall pattern.
Skin Biopsy
Multiple biopsies from different lesions are usually taken, because a single biopsy has limited sensitivity, and histological findings vary across lesions and over time. Key histological features include:
- Epidermotropism: the migration of atypical lymphocytes into the epidermis without accompanying spongiosis (edema), creating the distinctive pattern of individual malignant T cells "trafficking" through the outer skin layer.
- Pautrier microabscesses: clusters of atypical lymphocytes within the epidermis, often surrounding a Langerhans cell. Although pathognomonic for MF when present, they occur in only approximately 40% of biopsies — their absence does not rule out MF.
- Haloed lymphocytes: individual atypical lymphocytes surrounded by a clear halo within the epidermis.
- Atypical lymphocytes with cerebriform nuclei: the malignant T cells have characteristically folded, convoluted nuclei visible on high-power microscopy.
Immunohistochemistry (IHC)
IHC staining of biopsy material confirms the T-cell lineage and detects antigen loss: CD3+, CD4+, and importantly CD7– (loss) and variable CD5 loss. CD8+ variants exist but are uncommon.
T-Cell Receptor Gene Rearrangement (TCR PCR)
Polymerase chain reaction amplification of the TCR gamma or beta gene detects a clonal T-cell population in skin and peripheral blood. Identical clones in both skin and blood support a diagnosis of Sézary syndrome. Clonality analysis is interpreted alongside clinical and histological findings.
Blood Studies
- Complete blood count (CBC) with differential: absolute lymphocyte count, eosinophilia (common in SS)
- Flow cytometry: quantification of Sézary cells; CD4/CD8 ratio; CD4+CD7– and CD4+CD26– populations (loss of CD26 is a particularly specific marker of Sézary cells)
- Lactate dehydrogenase (LDH): elevated lactate dehydrogenase is an adverse prognostic factor
Staging Imaging
Computed tomography (CT) scan of chest, abdomen, and pelvis (or positron emission tomography/computed tomography (PET-CT) in advanced disease) assesses lymph node and visceral involvement for accurate TNMB staging. Lymph node biopsy is performed when nodes are enlarged to distinguish reactive (dermatopathic) from malignant involvement.
Treatment: Skin-Directed Therapies (Early Stage)
For patients with stage IA and IB disease (patch and thin plaque stage), the standard approach is skin-directed therapy aimed at controlling symptoms and preventing progression, rather than cure. These treatments are applied to the skin and minimize systemic side effects.
Topical Corticosteroids
High-potency topical steroids are often the first-line treatment for limited patch-stage disease. They reduce inflammation and pruritus and can produce partial or complete remission of individual lesions. Long-term use carries the standard risks of topical steroid atrophy, particularly problematic given the thin skin already characteristic of poikilodermatous patches.
Topical Mechlorethamine (Nitrogen Mustard)
Mechlorethamine gel is a U.S. Food and Drug Administration-approved topical alkylating agent. Its label covers stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have already received skin-directed therapy. It is applied daily to affected skin. In the 260-patient trial behind the gel (Lessin et al., 2013), 58.5% of patients on the gel responded by the main lesion score (Composite Assessment of Index Lesion Severity) and 46.9% by a whole-body score (Modified Severity-Weighted Assessment Tool). The main side effect is skin irritation and contact hypersensitivity; about 20% of patients on the gel left the trial because of drug-related skin irritation. Previously available only as compounded ointments, the U.S. Food and Drug Administration-approved 0.02% gel formulation standardized dosing.
Phototherapy
- Narrowband UVB (NB-UVB): the preferred phototherapy for thin patch-stage MF. Administered 2–3 times per week, it induces apoptosis in malignant T cells in the superficial epidermis. Well-tolerated and widely available. Less effective for thick plaques.
- PUVA (Psoralen + ultraviolet A, UVA): oral or bath psoralen (a photosensitizing agent) followed by ultraviolet A irradiation. Ultraviolet A penetrates more deeply than ultraviolet B (UVB), making PUVA more effective for plaque-stage disease. Risks include accelerated skin aging, cataracts, and long-term increased risk of squamous cell carcinoma and melanoma with cumulative exposure. Sun-protection precautions on treatment days are part of the treatment.
Total Skin Electron Beam Therapy (TSEBT)
TSEBT delivers low-energy electrons to the entire skin surface. Electrons penetrate only a few millimeters — deep enough to treat MF in the dermis and epidermis, but too shallow to cause significant internal organ exposure. It is highly effective for extensive patch and plaque disease and for early tumor-stage disease. TSEBT is available only at specialized academic centers with the required equipment and physics expertise. Responses are often durable, but MF commonly relapses after 2–3 years, and repeat courses are limited by cumulative skin toxicity.
Treatment: Systemic Therapies (Advanced Disease)
Advanced-stage MF (tumor stage, erythrodermic, Sézary syndrome, or visceral involvement) requires systemic therapy. Several agents are specifically U.S. Food and Drug Administration-approved for MF/CTCL; others are used off-label or in clinical trials. Conventional cytotoxic chemotherapy is generally not used in early lines because it produces transient responses without survival benefit and causes significant immunosuppression.
Bexarotene
Bexarotene is an oral retinoid X receptor (RXR) agonist that modulates T-cell differentiation and proliferation. U.S. Food and Drug Administration-approved for CTCL, it achieves approximately 45% overall response in previously treated patients. The most significant and nearly universal side effect is severe hypertriglyceridemia (high blood fats). In the label's 300 mg/m²/day group, 60% of patients were given lipid-lowering drugs, and atorvastatin was used in 48%. The label warns against combining bexarotene with gemfibrozil, because gemfibrozil raises the level of bexarotene in the blood. The label states that bexarotene induces (central) hypothyroidism in about half of all patients treated: thyroid-stimulating hormone (TSH) fell in about 60% and total thyroxine (T4) in about 45%, and 37% received thyroid hormone replacement. Bexarotene is a retinoid that causes birth defects; the label states it must not be given to a pregnant woman, and because it may weaken hormonal contraceptives, the label points to non-hormonal contraception.
Vorinostat
Vorinostat was the first histone deacetylase (HDAC) inhibitor approved by the U.S. Food and Drug Administration (FDA) (2006) for the treatment of CTCL in patients with progressive, persistent, or recurrent disease. It is taken orally. HDAC inhibitors work through epigenetic modification — they prevent the removal of acetyl groups from histone proteins, allowing genes involved in cell cycle arrest and apoptosis to remain accessible. Response rates in refractory CTCL are approximately 24–30%. Key side effects include fatigue, gastrointestinal symptoms, thrombocytopenia, and pulmonary embolism risk (requires monitoring).
Romidepsin
Romidepsin is an intravenous HDAC inhibitor (cyclic depsipeptide class). Its current U.S. Food and Drug Administration label covers CTCL in adults who have received at least one prior systemic therapy; the peripheral T-cell lymphoma use was removed from the label in 2021. Given on days 1, 8, and 15 of a 28-day cycle, it achieves response rates of approximately 34–38% in refractory CTCL, with particularly good responses in Sézary syndrome. Side effects include nausea, fatigue, QTc prolongation (cardiac rhythm monitoring required), and cytopenias. Infection risk is significant.
Mogamulizumab
Mogamulizumab is a humanized anti-CCR4 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC). CCR4 (CC-chemokine receptor 4) is highly expressed on malignant MF and Sézary cells, making it an excellent therapeutic target. U.S. Food and Drug Administration-approved in 2018 for previously treated MF and Sézary syndrome, it demonstrated superior progression-free survival vs. vorinostat (7.7 months vs. 3.1 months) in the landmark MAVORIC trial (Kim et al., 2018). Important considerations:
- Skin reactions: drug-related skin rash (drug eruption), which can resemble cutaneous graft-versus-host disease (GVHD), occurred in 25% (80 of 319) of patients in the label's main study — about one in four — and 18% of those cases were severe (grade 3). The label also reports fatal and life-threatening skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Because the rash can look like MF, it is told apart from MF progression by biopsy.
- Regulatory T-cell depletion: mogamulizumab eliminates CCR4+ regulatory T cells (Tregs), which can cause inflammatory autoimmune side effects. Critically, Treg depletion before allogeneic stem cell transplantation substantially increases the risk of severe and potentially fatal GVHD. The label reports severe (grade 3 or 4) acute GVHD, steroid-refractory GVHD and transplant-related deaths in patients who had an allogeneic stem cell transplant after mogamulizumab, with a higher risk when it was given within about 50 days before the transplant.
Brentuximab Vedotin
Brentuximab vedotin is an antibody-drug conjugate: an antibody aimed at the CD30 marker, carrying a cell-killing drug. In the ALCANZA trial (Prince et al., 2017), 128 previously treated patients with CD30-positive cutaneous T-cell lymphoma (mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma) were analysed. A response lasting at least 4 months occurred in 56.3% with brentuximab vedotin, compared with 12.5% with the doctor's choice of methotrexate or bexarotene. Nerve damage (peripheral neuropathy) occurred in 67% of patients on brentuximab vedotin.
Denileukin Diftitox-cxdl
Denileukin diftitox-cxdl is a fusion protein made of diphtheria toxin fragments joined to human interleukin-2. Its U.S. Food and Drug Administration label covers adults with relapsed or refractory stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy, and carries a boxed warning for capillary leak syndrome, including life-threatening or fatal cases. In its phase III trial (Foss et al., 2025), 36.2% of 69 patients responded, including 8.7% with a complete response; the median response lasted 8.9 months. Capillary leak syndrome occurred in 20.3% (grade 3 or worse in 5.8%).
Extracorporeal Photopheresis (ECP)
ECP is a specialized immunotherapy procedure particularly effective for Sézary syndrome and erythrodermic MF. The process involves:
- Leukapheresis: white blood cells (mononuclear cells — MNCs) are separated from the patient's blood by an apheresis machine.
- Ex vivo photoactivation: the collected MNCs are exposed to 8-methoxypsoralen (8-MOP) and ultraviolet A irradiation outside the body (ex vivo).
- Reinfusion: the treated (partially killed/altered) cells are returned to the patient, where they appear to induce an immune response against the malignant T-cell clone.
ECP is typically performed on two consecutive days per month. It is well-tolerated with few systemic side effects. Response rates of 30–80% in erythrodermic CTCL are reported, with best responses in patients with lower Sézary cell burdens and shorter disease duration. ECP is frequently combined with other systemic agents (bexarotene, interferon-alpha) for enhanced response.
Allogeneic Stem Cell Transplantation (Allo-SCT)
Allo-SCT offers curative potential for advanced MF and Sézary syndrome, with sustained complete remissions reported in a subset of patients — likely driven by graft-versus-lymphoma (GVL) effect. However, it carries significant treatment-related mortality (TRM) from infection, GVHD, and organ toxicity, and is reserved for younger, fit patients with advanced refractory disease. Patient selection and timing matter: the mogamulizumab label reports more transplant complications when the drug was given within about 50 days before transplant.
Prognosis
Prognosis in MF is strongly determined by disease stage at diagnosis. The reassuring reality for most patients — who present with early patch or plaque disease — is that survival is not substantially different from age-matched controls when disease remains at stage IA.
- Stage IA (patches <10% BSA, no nodal/blood/visceral involvement): median survival exceeds 20 years; disease-specific mortality low; most patients die of unrelated causes.
- Stage IB–IIA (patches/plaques ≥10% BSA; reactive lymph nodes): median survival approximately 11–15 years.
- Stage IIB (tumors): median survival approximately 3.2 years.
- Stage III (erythroderma without significant blood involvement): median survival approximately 4–6 years.
- Sézary syndrome (Stage IVA1): median survival approximately 2–4 years.
- Stage IVB (visceral involvement): median survival approximately 1 year.
Adverse prognostic factors beyond stage include: elevated lactate dehydrogenase, large-cell transformation, folliculotropic MF (a variant with follicular involvement that is more aggressive), and older age at diagnosis. Folliculotropic MF is staged and treated as if it were one stage higher than its skin involvement would suggest.
A 2010 study of 1,502 patients from one UK centre (Agar et al.) found that 71% presented at an early stage; the disease progressed in 34%, and 26% died of MF or Sézary syndrome. Independent markers of worse survival were advanced skin (T) stage, the tumor clone in the blood without Sézary cells, raised lactate dehydrogenase and the folliculotropic form.
Quality of Life and Patient Guidance
Living with MF presents unique challenges — the combination of a chronic, incurable (at early stage), visible skin disease with a cancer diagnosis creates significant psychological burden. Key considerations:
The Pruritus Problem
Pruritus (itch) is often the most debilitating symptom, frequently described by patients as "maddening" and far more distressing than the visible appearance of lesions. Scratching damages already fragile skin, creates entry points for infection, and disrupts sleep. Treatments targeting itch specifically — including antihistamines (limited efficacy), gabapentin, aprepitant (NK1 receptor antagonist), and dupilumab (in select cases) — may provide relief. Importantly, treating the underlying MF effectively is the most reliable way to control pruritus.
Psychosocial Burden
The combination of a cancer diagnosis, chronic visible skin changes, severe itch, and prolonged diagnostic uncertainty (many patients receive incorrect diagnoses for years before MF is confirmed) is associated with high rates of anxiety and depression. Peer support groups — particularly those specifically for CTCL/MF — can provide community, information, and emotional support that general cancer support groups may not offer. The Cutaneous Lymphoma Foundation (CLF) maintains patient education resources and a patient registry.
Infection Risk
Disrupted skin barrier and immunosuppressive treatments significantly increase infection risk. Staphylococcus aureus colonization of MF skin lesions is nearly universal and can trigger flares; many dermatologists incorporate skin decolonization protocols (dilute bleach baths, mupirocin nasal ointment) into routine management. Increased warmth, pain, pus (purulent discharge) and fever are signs of skin infection, which is treated early.
Questions Patients Often Raise With Their Dermatologist
- Whether care at a center specializing in cutaneous lymphoma is available
- How many biopsies are needed, and from which lesions
- Whether T-cell receptor gene clonality testing has been done on the biopsy
- Whether narrowband ultraviolet B or PUVA phototherapy fits the disease stage
- Which clinical trials are currently open
- How often staging evaluations (blood tests, imaging) are repeated
- Which signs of progression call for an earlier visit
Clinical Trials
Given the rarity of MF and the limited curative options available outside of allogeneic transplant, clinical trials are one of the routes to newer treatments for advanced or refractory disease. Active trials can be identified at clinicaltrials.gov by searching "mycosis fungoides" or "cutaneous T-cell lymphoma."
Key Research Papers
- Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90(1):354–371. — PubMed PMID: 9207472
- Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–1722. — PubMed PMID: 17540844
- Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021;7(1):61. — PubMed PMID: 34446710
- Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204. — PubMed PMID: 30100375
- Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–3115. — PubMed PMID: 17577020
- Piekarz RL, Frye AR, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410–5417. — PubMed PMID: 19826128
- Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005;141(3):305–311. — PubMed PMID: 15781671
- Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 1):1–37. — PubMed PMID: 24354653
- Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–4491. — PubMed PMID: 20697094
- Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–39. — PubMed PMID: 16960145
- Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785. — PubMed PMID: 15692063
- Jahan-Tigh RR, Ryan C, Obermoser G, Schwarzenberger K. Flow cytometry. J Invest Dermatol. 2012;132(10):1–6. — PubMed PMID: 22971922
- Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25–32. — PubMed PMID: 23069814
- Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566. — PubMed PMID: 28600132
- Foss FM, Kim YH, Prince HM, et al. Efficacy and safety of denileukin diftitox-cxdl, an improved purity formulation of denileukin diftitox, in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2025;43(10):1198–1209. — PubMed PMID: 39700456
- Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730–4739. — PubMed PMID: 20855822
Search PubMed for more: Mycosis fungoides treatment Cutaneous T-cell lymphoma CTCL Sézary syndrome